A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis

Overview

Journal Kidney Int Rep

Publisher Elsevier

Date 2025 Jan 15

PMID 39810768

Authors

Daniel Steiner

Daniel Kraemmer

Stephan Nopp

Oliver Konigsbrugge

Cihan Ay

Affiliations

Soon will be listed here.

Abstract

Introduction: Factor XI/XIa (FXI/XIa) has emerged as a potential target for antithrombotic therapy, driven by preclinical evidence showing the role of FXI/XIa inhibition for preventing thrombosis without impeding hemostasis. This is particularly promising for patients at high risk of both thromboembolic events and bleeding, such as patients with end-stage kidney disease (ESKD) on hemodialysis (HD).

Methods: We systematically searched Embase, MEDLINE, and ClinicalTrials.gov for randomized controlled trials evaluating FXI/XIa inhibitors in patients with ESKD on HD, without restricting inclusion to specific comparators or indications. Interventional treatment arms were pooled, and study results were synthesized by fitting random-effects models, calculating odds ratios (ORs) and 95% confidence intervals (CIs).

Results: Five phases 2 studies encompassing 1270 participants were identified, investigating gruticibart, IONIS-FXI osocimab, or fesomersen in the general HD population and using placebo as a comparator. Four studies were fully published and included in the meta-analysis. Use of FXI/XIa inhibitors was associated with an OR of 0.80 (95% CI = 0.47-1.35) for clinically relevant bleeding, 0.51 (95% CI = 0.21-1.28) for major bleeding, and 0.90 (95% CI = 0.49-1.68) for clinically relevant nonmajor bleeding. The ORs for thromboembolic events and all-cause mortality were 0.66 (95% CI = 0.28-1.56) and 0.46 (95% CI = 0.15-1.40), respectively.

Conclusion: Currently available evidence does not indicate a significantly increased bleeding risk of FXI/XIa inhibitors in patients with ESKD on HD compared to placebo. Their efficacy and their association with all-cause mortality need to be investigated in sufficiently powered, randomized controlled phase 3 trials.

References

Verhamme P, Yi B, Segers A, Salter J, Bloomfield D, Buller H . Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021; 385(7):609-617. DOI: 10.1056/NEJMoa2105872. View

Gill D, Georgakis M, Laffan M, Sabater-Lleal M, Malik R, Tzoulaki I . Genetically Determined FXI (Factor XI) Levels and Risk of Stroke. Stroke. 2018; 49(11):2761-2763. DOI: 10.1161/STROKEAHA.118.022792. View

Reinecke H, Brand E, Mesters R, Schabitz W, Fisher M, Pavenstadt H . Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2008; 20(4):705-11. DOI: 10.1681/ASN.2007111207. View

Salomon O, Steinberg D, Koren-Morag N, Tanne D, Seligsohn U . Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008; 111(8):4113-7. DOI: 10.1182/blood-2007-10-120139. View

Haddaway N, Page M, Pritchard C, McGuinness L . : An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2023; 18(2):e1230. PMC: 8958186. DOI: 10.1002/cl2.1230. View

Konstantinidis I, Nadkarni G, Yacoub R, Saha A, Simoes P, Parikh C . Representation of Patients With Kidney Disease in Trials of Cardiovascular Interventions: An Updated Systematic Review. JAMA Intern Med. 2015; 176(1):121-4. DOI: 10.1001/jamainternmed.2015.6102. View

Occhipinti G, Laudani C, Spagnolo M, Finocchiaro S, Mazzone P, Faro D . Pharmacological and clinical appraisal of factor XI inhibitor drugs. Eur Heart J Cardiovasc Pharmacother. 2024; 10(3):245-258. DOI: 10.1093/ehjcvp/pvae002. View

Peyvandi F, Palla R, Menegatti M, Siboni S, Halimeh S, Faeser B . Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012; 10(4):615-21. DOI: 10.1111/j.1538-7836.2012.04653.x. View

Rao S, Kirsch B, Bhatt D, Budaj A, Coppolecchia R, Eikelboom J . A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation. 2022; 146(16):1196-1206. DOI: 10.1161/CIRCULATIONAHA.122.061612. View

10.

Molnar A, Bota S, McArthur E, Lam N, Garg A, Wald R . Risk and complications of venous thromboembolism in dialysis patients. Nephrol Dial Transplant. 2017; 33(5):874-880. DOI: 10.1093/ndt/gfx212. View

11.

Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F . Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia. 2015; 21(4):496-501. DOI: 10.1111/hae.12628. View

12.

De Vriese A, Caluwe R, Van Der Meersch H, De Boeck K, De Bacquer D . Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol. 2021; 32(6):1474-1483. PMC: 8259651. DOI: 10.1681/ASN.2020111566. View

13.

Pokorney S, Chertow G, Al-Khalidi H, Gallup D, Dignacco P, Mussina K . Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022; 146(23):1735-1745. DOI: 10.1161/CIRCULATIONAHA.121.054990. View

14.

Shoamanesh A, Mundl H, Smith E, Masjuan J, Milanov I, Hirano T . Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022; 400(10357):997-1007. DOI: 10.1016/S0140-6736(22)01588-4. View

15.

Konigsbrugge O, Ay C . Atrial fibrillation in patients with end-stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation. Res Pract Thromb Haemost. 2019; 3(4):578-588. PMC: 6781927. DOI: 10.1002/rth2.12250. View

16.

Liu T, Hashizume K, Krieg E, Chen H, Mukaida Y, Thelen K . Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clin Transl Sci. 2024; 17(4):e13784. PMC: 10985948. DOI: 10.1111/cts.13784. View

17.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

18.

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

19.

Weitz J, Strony J, Ageno W, Gailani D, Hylek E, Lassen M . Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021; 385(23):2161-2172. PMC: 9540352. DOI: 10.1056/NEJMoa2113194. View

20.

Konigsbrugge O, Meisel H, Beyer A, Schmaldienst S, Klauser-Braun R, Lorenz M . Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. J Thromb Haemost. 2021; 19(12):2984-2996. DOI: 10.1111/jth.15508. View